Of interest, in the bevacizumab‐treated GBM cohort (S/RTx/CTx/Bev), the CD8/CD3 ratio was elevated compared to treatment‐naive GBM, suggesting that VEGF blockade affects T‐cell composition within tumors, which is in line with previous observations (Huang et al, 2012; Chung et al, 2013; Motz et al, 2014). The gene discussed is VEGFA; the disease is glioblastoma.